Submitted by GAtherton on 10 June 2016
Isavuconazole is commercially available in the US and in Germany and the UK but not yet in all EU countries nor elsewhere.
Clinigen Group PLC (LON:CLIN) and Swiss group Basilea have started a managed access programme for a treatment for invasive fungal infections including aspergillosis throughout Europe.
Through the programme, isavuconazole will be available in European countries where it has been approved but is not yet commercially available.
The drug is commercially available in the US and in Germany and the UK but not yet in all EU countries nor elsewhere.
Access to isavuconazole will require a request from a doctor for eligible individual patients.
Steve Glass, Clinigen’s group managing director, said: “Invasive fungal infections pose a fatal threat to immuno-compromised patients. It is therefore crucial that new treatment options like isavuconazole are made available and can be accessed by those who need it at the first possible opportunity.”
News archives
-
Title
Date
